Literature DB >> 9663238

Success rates of nasolacrimal duct probing at time intervals after 1 year of age.

R M Robb1.   

Abstract

OBJECTIVE: The purpose of the study was to determine the success rate of probing for congenital nasolacrimal duct obstruction after 1 year of age.
DESIGN: A record review. PARTICIPANTS AND INTERVENTION: Two hundred fifty-two patients with 303 obstructed nasolacrimal ducts underwent probing and irrigation by the author between 1971 and 1997 while under brief general anesthesia. MAIN OUTCOME MEASURES: Successful outcome of probing was defined as absence of tearing and discharge in the affected eye.
RESULTS: The overall cure rate in all patients was 92%, varying from 88.9% to 96.8% at different age intervals up to and beyond 3 years of age. Chi-square analysis showed no significant change in cure rate with increasing age.
CONCLUSION: Probing for congenital nasolacrimal duct obstruction beyond 1 year of age is highly successful, and the cure rate does not vary significantly at intervals of increasing age.

Entities:  

Mesh:

Year:  1998        PMID: 9663238     DOI: 10.1016/S0161-6420(98)97038-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  32 in total

1.  Value of nasal endoscopy and probing in the diagnosis and management of children with congenital epiphora.

Authors:  C J MacEwen; J D Young; C W Barras; B Ram; P S White
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

2.  Management of childhood epiphora.

Authors:  J E Marr; A Drake-Lee; H E Willshaw
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

3.  Long-term results of probing guided with soft cannula in children with congenital nasolacrimal duct obstruction.

Authors:  Dilek Yuksel; Pınar Altiaylik Ozer
Journal:  Jpn J Ophthalmol       Date:  2013-11-16       Impact factor: 2.447

4.  [Increased prevalence of congenital dacryostenosis following cesarean section].

Authors:  Claudia Kuhli-Hattenbach; M Lüchtenberg; C Hofmann; T Kohnen
Journal:  Ophthalmologe       Date:  2016-08       Impact factor: 1.059

5.  Office probing for treatment of nasolacrimal duct obstruction in infants.

Authors:  Aaron M Miller; Danielle L Chandler; Michael X Repka; Darren L Hoover; Katherine A Lee; Michele Melia; Paul J Rychwalski; David I Silbert; Roy W Beck; Eric R Crouch; Sean Donahue; Jonathan M Holmes; Graham E Quinn; Nick A Sala; Susan Schloff; David K Wallace; Nicole C Foster; Kevin D Frick; Richard P Golden; Scott R Lambert; D Robbins Tien; David R Weakley
Journal:  J AAPOS       Date:  2014-02       Impact factor: 1.220

6.  [Treatment of congenital lacrimal duct obstruction: A prospective clinical cohort study].

Authors:  J Heichel; F Bachner; A Schmidt-Pokrzywniak; H-G Struck; U Stuhlträger; T Bredehorn-Mayr
Journal:  Ophthalmologe       Date:  2015-10       Impact factor: 1.059

7.  Clinical outcomes of initial and repeated nasolacrimal duct office-based probing for congenital nasolacrimal duct obstruction.

Authors:  Deok Sun Cha; Hwa Lee; Min Soo Park; Jong Mi Lee; Se Hyun Baek
Journal:  Korean J Ophthalmol       Date:  2010-10-05

8.  Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years.

Authors:  Michael X Repka; Danielle L Chandler; Roy W Beck; Eric R Crouch; Sean Donahue; Jonathan M Holmes; Katherine Lee; Michele Melia; Graham E Quinn; Nick A Sala; Susan Schloff; David I Silbert; David K Wallace
Journal:  Ophthalmology       Date:  2007-11-08       Impact factor: 12.079

9.  The course of epiphora after failure of silicone intubation for congenital nasolacrimal duct obstruction.

Authors:  Yanir Kassif; Uri Rehany; Michal David; Anna Popko; Shimon Rumelt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

10.  Paediatric endoscopic endonasal dacryocystorhinostomy in congenital nasolacrimal duct obstruction.

Authors:  Igal Leibovitch; Dinesh Selva; Angelo Tsirbas; Edward Greenrod; John Pater; Peter J Wormald
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.